Market Research Report
Perfusion Systems Market (Cardiopulmonary Perfusion, by Component (Heart-lung Machines, Oxygenators), Ex Vivo Organ Perfusion, Technique (Hypothermic, Normothermic), Cell Perfusion, by Type (Bioreactor, Microfluidic)) - Global Forecast to 2021
|Published by||MarketsandMarkets||Product code||494467|
|Published||Content info||154 Pages
Delivery time: 1-2 business days
|Perfusion Systems Market (Cardiopulmonary Perfusion, by Component (Heart-lung Machines, Oxygenators), Ex Vivo Organ Perfusion, Technique (Hypothermic, Normothermic), Cell Perfusion, by Type (Bioreactor, Microfluidic)) - Global Forecast to 2021|
|Published: April 24, 2017||Content info: 154 Pages||
The perfusion systems market is projected to reach USD 1,198.8 million by 2021, at a CAGR of 3.9% during the forecast period 2016-2021. The growth of the market can be attributed to the increasing prevalence of cardiovascular and respiratory diseases, initiatives by governments and NGOs to encourage organ donation, increasing investment in cell-based research, and developments in biologics manufacturing.
The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region. The global cardiopulmonary perfusion systems market is segmented based on components into oxygenators, heart-lung machines, perfusion pumps, cannulas, monitoring systems, and other components. While the oxygenators segment held the largest share of the global cardiopulmonary perfusion systems market in 2016, it is the perfusion pumps segment that is projected to grow at the highest CAGR during the forecast period.
The global cell perfusion systems market is segmented based on the type, as bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure-driven perfusion systems, and small-mammal organ perfusion systems. The bioreactor perfusion systems segment held the largest share of the market in 2016 and is also projected to register highest CAGR during the forecast period.
Based on technique, the ex vivo organ perfusion systems market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment accounted for the largest share of the market in 2016 and is also projected to grow at the highest CAGR during the forecast period.
On the basis of region, the global perfusion systems market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America held the largest share of the global market in 2016, followed by Europe.
The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, mainly due to the increasing aging population, rising organ donations and transplants in Japan, growth of the pharmaceutical and biotechnology R&D industry and CROs in China, and growing pharmaceutical & biotechnology industry and government initiatives in India.
The report studies factors affecting the growth of the perfusion systems market and analyzes opportunities and challenges in the market for stakeholders. It provides details of the competitive landscape of market leaders and analyzes micro-markets on their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market and help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned strategies to strengthen their market shares.
The report provides insights on the following pointers:
Top 13 companies analyzed for this studies are - Getinge AB (Sweden), Medtronic plc (Ireland), Terumo Corporation (Japan), LivaNova PLC (U.K.), XENIOS AG (Germany), Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Nipro Corporation (Japan), Harvard Bioscience, Inc. (U.S.), ALA Scientific Instruments, Inc. (U.S.), Lifeline Scientific, Inc. (U.S.), and XVIVO Perfusion AB (Sweden).
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.